

# Preparation of 9-Substituted Pyridine-Stretched Adenines and Hypoxanthine

Julia A. Crawford,<sup>a</sup> William Fraser,<sup>b</sup> Christopher A. Ramsden<sup>a\*</sup>

<sup>a</sup> Lennard-Jones Laboratories, School of Physical and Geographical Sciences, Keele University, Keele, Staffordshire, UK ST5 5BG

<sup>b</sup> Pharmaceutical Sciences Research Institute, Aston University, Aston Triangle, Birmingham, B4 7ET, UK

Fax: 01782 712378


E-mail: c.a.ramsden@chem.keele.ac.uk

Received: [Draft of 09/10/08]

**Abstract:** Please overwrite this text with a written abstract, which should summarize the results and conclusions of the research performed.

**Key words:** imidazoles, amines, *lin*-pyridoadenines, soft electrophile, tricyclic heterocycle.


Several groups have investigated modification of purine nucleosides by insertion of a third ring between the imidazole and pyrimidine fragments. The earliest investigation was by Leonard and coworkers who described the synthesis of the benzene-stretched adenosine analogue **1**.<sup>1-4</sup> Later the 2 $\phi$ -deoxy derivative **3** was prepared.<sup>5</sup> Subsequently other groups have prepared tricyclic analogues<sup>6-8</sup> and aspects of this work have been reviewed.<sup>9</sup> For some time we have been interested in preparing pyridine-stretched purine derivatives and have previously described the adenosine analogue **2** and the corresponding inosine analogue.<sup>10</sup> More recently we prepared the 2 $\phi$ -deoxy analogues of adenosine **4** and inosine:<sup>11</sup> these have been incorporated into oligonucleotides and their duplex-forming properties investigated.<sup>12</sup> With the objective of providing access to a wider range of pyridine-stretched purine derivatives, we have investigated the preparation of 9-substituted derivatives of the general types **5** and **6** (R  $\bar{N}$ H) and now report the results of these studies.



**Figure 1**

Two features of pyridine-stretched nucleosides may be advantageous: (i) the presence of the nitrogen atom in

position 4 may enhance the stability of triplex-forming oligonucleotides (TFOs) targeted to DNA; (ii) their preparation *via* addition-elimination reactions of 5-aminoimidazoles may make them more easily accessible than the benzene-stretched derivatives. The 9-unsubstituted derivatives **2** and **4** were prepared *via* reaction of ethoxymethylene malononitrile [EMMN: (NC)<sub>2</sub>C=CHOEt] with the appropriate 5-aminoimidazoles **8**, which were obtained by reduction of the 5-nitroimidazoles **7**.<sup>10,11</sup> The preparation of the 9-substituted derivatives **5** and **6** (R  $\bar{N}$ H) therefore requires a C-substituted analogue of EMMN that reacts selectively at the C-4 position of 5-aminoimidazoles **8**.



**Figure 2**


In an earlier study,<sup>13,14</sup> we showed that 5-aminoimidazoles<sup>15</sup> can react as either N- or C-nucleophiles and demonstrated a correlation between the position of reaction and the softness of the electrophile, measured by the AM1 calculated LUMO energy. Thus, EMMN [(NC)<sub>2</sub>C=CHOEt] (LUMO -0.62 eV) gives exclusively C-adducts whereas diethyl ethoxymethylenemalonate [EMME: (EtO<sub>2</sub>C)<sub>2</sub>C=CHOEt] (LUMO -0.27 eV) gives exclusively N-adducts. The general conclusion of our studies of a range of electrophiles was that reagents with a calculated (AM1) LUMO energy < 0.5 eV react predominantly at the C-4 position of 5-aminoimidazoles.<sup>14</sup> A C-substituted analogue of EMMN with a LUMO energy < 0.5 eV was therefore required in order to produce precursors of the 9-substituted derivatives **5** and **6**. Table 1 shows the AM1 calculated frontier orbital energies of selected electrophiles.

From Table 1 it is clear that introduction of a second ethoxy substituent into EMME (Entries 2 and 4) will increase the LUMO energy and probably favour N-adduct formation. However, replacement of the ethoxy group by a methylsulfonyl substituent (Entries 4 and 7) significantly reduces the LUMO energy and intro-

duction of a second methylsulfonyl group (Entry 8) leads to an electrophile with an exceptionally low energy LUMO. We therefore anticipated that 2-(bis-methylsulfonylmethylene) malononitrile **9** [(NC)<sub>2</sub>C=C(SMe)<sub>2</sub>] would give C-adducts with 5-aminoimidazoles and thus provide access to 9-methylsulfonyl derivatives that can be further manipulated. Although we have not previously worked with the reagent **9**, it is readily prepared in good yield by reaction of malononitrile with carbon disulfide and methyl iodide in the presence of potassium fluoride.<sup>16</sup> The LUMO energy lowering effect of an alkylsulfonyl substituent appears to be general: a similar effect is observed for the corresponding diesters (Entries 1 and 3).

**Table 1** AM1 calculated frontier orbital energies of electrophiles

Entry	Electrophile	LUMO (eV)	HOMO (eV)
1	(EtO <sub>2</sub> C) <sub>2</sub> C=CH.OEt	-0.27	-10.15
2	(NC) <sub>2</sub> C=C(OEt) <sub>2</sub>	-0.29	-9.53
3	(EtO <sub>2</sub> C) <sub>2</sub> C=CH.SMe	-0.60	-9.05
4	(NC) <sub>2</sub> C=CH.OEt	-0.62	-10.05
5	(NC) <sub>2</sub> C=C(SMe)NH <sup>n</sup> Pr	-0.71	-8.93
6	(NC) <sub>2</sub> C=C(SMe)NHPH	-0.90	-8.87
7	(NC) <sub>2</sub> C=CH.SMe	-0.95	-9.11
8	(NC) <sub>2</sub> C=C(SMe) <sub>2</sub>	-1.31	-8.91




**Scheme 1**

In these studies we have used 5-amino-1,2-dimethylimidazole **12** as a model compound. A solu-

tion of the amine **12** in THF was generated by catalytic reduction (H<sub>2</sub>/Pd/C) of 1,2-dimethyl-5-nitroimidazole **7** (R<sup>1</sup> = R<sup>2</sup> = Me). The amine solution was filtered through celite into a flask containing a five-fold excess of 2-(bis-methylsulfonylmethylene) malononitrile **9** and the mixture stirred at 50 °C overnight. Workup gave a yellow-orange solid that was identified as the C-adduct **13**. The yield based on nitroimidazole starting material was 47%. No other products were identified in the reaction mixture. An analytically pure sample (mp 197-8 °C) was prepared by flash chromatography and recrystallisation from EtOAc/MeOH. The structure **13** was fully supported by its spectroscopic properties. In particular the <sup>1</sup>H NMR spectrum showed a broad singlet at δ 7.05 corresponding to the NH<sub>2</sub> group and the absence of an imidazole ring proton, which would be characteristic of the isomeric N-adduct. The constitution C<sub>10</sub>H<sub>11</sub>N<sub>5</sub>S was confirmed by mass spectrometry and elemental analysis.

Treatment of a methanol solution of the C-adduct **13** with aqueous NaOH at 60 °C resulted in cyclisation to the imidazo[4,5-*b*]pyridine **14** (mp 300 °C, 86%). Subsequent treatment with hot triethyl orthoformate gave the ethyl imidate **15** (mp 197-200 °C, 87%) which upon reaction with hot ethanolic ammonia gave the tricyclic amine **16** (mp 252-5 °C, 85%). The properties of the amine **16** were fully in accord with the proposed structure. The <sup>1</sup>H NMR spectrum showed C-Me, S-Me and N-Me singlets, at δ 2.66, 2.94 and 3.75 respectively, together with a broad NH<sub>2</sub> signal (δ 8.32) and a single ring proton (δ 8.40). The mass spectrum showed a strong molecular ion (*m/z* 260). Compound **16** is an example of a 9-substituted pyridine-stretched adenine derivative and the route shown in Scheme 1 employing the soft bis-methylsulfonyl electrophile **9**, therefore establishes a viable route to derivatives of this type. Treatment of compound **16** with hot 2M HCl (2 h) gave the pyridine-stretched hypoxanthine derivative **17** (mp >350 °C, 74%) which was fully characterised.

Reaction of the ethyl imidate **15** with *n*-propylamine under various conditions gave only the amidine **18** and not the anticipated tricyclic *N*-*n*-propyl derivative **19**. All attempts at cyclisation were unsuccessful, although similar cyclisations of 9-unsubstituted derivatives have been reported.<sup>15</sup>



**Figure 3**

Inspection of Table 1 reveals that amino substituted electrophiles (Entries 5 and 6) also have a low energy


LUMO and might be expected to react selectively to give C-adducts. In principle these reagents could provide a direct route to 9-amino derivatives, e.g. **5** and **6** ( $R^3 = \text{NHR}$ ). We therefore investigated the reactions of the reagents **10** and **11** with the aminoimidazole **12** but in neither case was any reaction detected under a variety of conditions. As might be expected, the nitrogen lone pair appears to reduce the reactivity of the electrophile and although the LUMO energy is an indicator of regioselectivity it is not a measure of reactivity. To prepare 9-amino derivatives we next investigated methods of modifying the 9-methylsulfanyl substituent.

Reaction of compound **16** with *n*-propylamine did not result in substitution of the thiomethyl group by the amine. It was therefore decided to oxidize the thioether to the methyl sulfone which is a better leaving group. To avoid oxidation of the 8-amino group, *N*-protected derivatives were prepared. Reaction with either acetic anhydride or acetic anhydride/ pyridine under various conditions gave the *N,N*-diacetyl derivative **20** (mp 178-183 °C). In one experiment a very low yield of material (mp 218-220 °C) that appeared to be the mono-acetyl derivative was obtained but attempts to repeat this by variation of method or work-up were unsuccessful. Attempts to remove one acetyl group using calcium carbonate in MeOH/H<sub>2</sub>O<sup>99</sup> resulted in removal of both acetyl groups. We therefore decided to carry out further work on the diacetyl derivative **20**. The 8-amino group was also protected as the *t*-butoxycarbonyl (*t*-Boc) derivative **21** (mp 167 °C (d): 83%) by reaction with di-*t*-butyl dicarbonate in 1,4-dioxane (6 h at 120 °C).

Oxidation of the *N,N*-diacetyl derivative **20** with one equivalent of 3-chloroperoxybenzoic acid (MCPBA) in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C gave a poor yield (11%) of the sulfoxide **22**. A similar procedure gave a better yield (63%) of the sulfoxide **23**. Both sulfoxides were fully characterized and showed the expected spectroscopic properties. Oxidation using two equivalents of MCPBA gave the sulfones **24** (mp 185-6 °C, 67%) and **25** (mp 100 °C (d), 65%), respectively. Further studies were carried out using the *t*-Boc protected sulfone **25**, which was obtained in greater overall yield from the amine **16**.


To demonstrate nucleophilic substitution of the methyl sulfonyl substituent we initially reacted compound **25** with sodium ethoxide in ethanol at room temperature. A single product was formed and, after chromatographic isolation in 24% yield, was identified as the 9-ethoxy derivative (mp 204 °C (d)). <sup>1</sup>H NMR spectroscopy clearly showed the product contained an ethyl substituent ( $\delta$  1.67 and 5.34) and the absence of a methyl sulfone signal ( $\delta$  ~3.9). Excellent yields of substitution products were obtained, without chromatography, when the sulfone **25** was reacted with alkylamines. With *n*-propylamine in CH<sub>2</sub>Cl<sub>2</sub> at room temperature (2 h) a 98% yield of the secondary amine **27** (mp 218 °C(d)) was obtained. A similar procedure

gave the *n*-butyl derivative **28** (mp 220 °C (d)) in 93% yield. The use of 9-sulfones, e.g. **25**, therefore provides access to 8,9-diamino derivatives in the pyridine-stretched purine series.



Scheme 2

The application of this methodology to the synthesis of 2'-deoxyribonucleotide analogues requires the reaction of 2-(bis-methylsulfanylmethylene) malononitrile **9** with 5-aminoimidazole **29** to give the C-adduct **30**. We have therefore made a preliminary investigation: reaction of the amine **29**<sup>11</sup> with electrophile **9** gave a single product which after chromatography was identified as the desired adduct **30** (mp 98-100 °C, 15%), which was fully characterized. The yield was low and requires optimization but the regioselectivity of the reaction demonstrates that this is a potential route to 9-substituted derivatives.



Scheme 3

IR spectra were obtained using a Thermo-Nicolet Avatar 370 Fourier Transform Infra Red spectrometer. Mass spectra were obtained at the EPSRC National Mass Spectrometry Centre, University of Wales Swansea and were either low resolution electron impact (EI/LR), low resolution electrospray (ES/LR) or high resolution electrospray (ES/HR). Melting points were measured on a Stuart Scientific SMP3 melting point apparatus. NMR spectra were recorded on a Bruker Advance DPX300 NMR spectrometer in CDCl<sub>3</sub> or d<sub>6</sub>-DMSO. Chemical shifts are quoted as ppm relative to TMS as internal standard. Solvents were dried as follows: THF was heated under reflux over, and then distilled from, sodium wire and benzophenone; DMF was dried by distillation, and then standing, over 4Å molecular sieves; pyridine was refluxed over KOH and allowed to stand over 4Å molecular sieves; 1,4-dioxane was refluxed over sodium and benzophenone, distilled off and stored over molecular sieves under a nitrogen atmosphere. TLC was carried out on aluminium backed 0.2mm silica gel and visualised with 254nm fluorescent indicator. Microanalyses were conducted through the Elemental Analysis Service at London Metropolitan University. AM1 calculations<sup>17</sup> were performed using the MOPAC programme in CS Chem3D (CambridgeSoft Corporation). Calculated frontier orbital energies vary with configuration but variations in the values recorded in Table 1 do not change the conclusions.

2-(Bis-methylsulfanylmethylene)malononitrile **9**<sup>16</sup> and 2-(methylsulfanyl-phenylaminomethylene) malononitrile **11**<sup>18</sup> were prepared by literature methods.

#### 2-(Methylsulfanyl-propylaminomethylene)-malononitrile **10**

2-(Bis-methylsulfanylmethylene)malononitrile **9** (4.00 g, 23.5 mmol) was dissolved in ethanol (25 mL) with stirring. *n*-Propylamine (1 mL, 11.8 mmol) was added dropwise over one hour and the mixture left to stir overnight. The solvent was then removed under reduced pressure and the solid product purified by column chromatography eluting with CH<sub>2</sub>Cl<sub>2</sub> to remove the starting material followed by 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give the product **10** (1.66 g, 78%); pale pink solid; mp 119-122 °C.

IR (KBr): 632, 864, 920, 1153, 1248, 1290, 1302, 1364, 1419, 1442, 1467, 1500, 1548, 2187, 2206, 2877, 2935, 2964, 3306 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.99 (t, *J* = 7.0 Hz, 3H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.67 (sextet, *J* = 7.0 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.68 (s, 3H, SCH<sub>3</sub>), 3.53 (q, *J* = 7.0 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 6.31 (br s, 1H, NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 11.00 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 17.55 (SCH<sub>3</sub>), 23.31 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 48.33 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 52.22 (C(CN)<sub>2</sub>), 115.35 (CN), 115.64 (CN), 174.69 (C=C(CN)<sub>2</sub>).

MS (EI/LR): *m/z* (%) = 181 (38) [M<sup>+</sup>], 166 (9), 152 (18), 140 (13), 127 (15), 109 (12), 108 (19), 92 (58),

79 (15), 74 (22), 68 (22), 61 (63), 48 (25), 47 (33), 45 (40), 43 (75), 41 (100).

Anal. Calcd for C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>S (181.26): C, 53.01; H 6.12; N 23.18.

Found: C, 52.93; H, 6.17; N, 23.05.

#### 2-[(5-Amino-1,2-dimethyl-1*H*-imidazol-4-yl)-methylsulfanyl-methylene]malononitrile **13**

1,2-Dimethyl-5-nitroimidazole **7** (R<sup>1</sup> = R<sup>2</sup> = Me) (1.58 g, 11.2 mmol) and 5% Pd/C catalyst (1.20 g) were placed in a flask with dry THF (125 mL). The resulting mixture was hydrogenated at rt and atmospheric pressure, with vigorous stirring, over two hours. The reaction was monitored by TLC (Et<sub>2</sub>O) and showed the consumption of all starting material. The product mixture was filtered through dry celite, in an enclosed system under argon, into a flask containing 2-(bis-methylsulfanylmethylene) malononitrile **9** (9.64 g, 56.5 mmol). The reaction was stirred at 50 °C, under argon, overnight giving an orange-brown solution. The solvent was removed under reduced pressure at rt and the residue treated with liquid nitrogen-chilled EtOAc (100 mL). The solution was then filtered to give a yellow-orange solid. The crude product **13** was used without further purification (yield over two stages 47%).

An analytical sample was prepared by dissolving the solid in a minimum amount of MeOH followed by flash column chromatography (EtOAc as eluent). The relevant fractions were combined and the solvent removed by rotary evaporation giving a yellow solid that was recrystallised (EtOAc: MeOH 5:3) to give the product **13** (0.70 g, 27%); brilliant yellow crystals; mp 197-198 °C.

IR (KBr): 1313, 1489, 1603, 2213, 2251, 3469 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 2.23 (s, 3H, S-CH<sub>3</sub>), 2.49 (s, 3H, C-CH<sub>3</sub>), 3.34 (s, 3H, N-CH<sub>3</sub>), 7.05 (br s, 2H, NH<sub>2</sub>).

<sup>13</sup>C NMR (d<sub>6</sub>-DMSO): δ = 13.22 (C-CH<sub>3</sub>), 17.81 (S-CH<sub>3</sub>), 29.38 (N-CH<sub>3</sub>), 60.64 (methylene-C1), 113.70 (imidazole-C5), 116.85 (CN), 143.52 (imidazole-C4), 147.64 (imidazole-C2), 164.26 (methylene-C2).

MS (EI/LR): *m/z* (%) = 233 (100) [M<sup>+</sup>], 218 (8), 200 (22), 187 (21), 161 (17), 123 (4), 104 (10), 84 (22), 56 (63), 49 (29), 42 (24).

Anal. Calcd for C<sub>10</sub>H<sub>11</sub>N<sub>5</sub>S (233.29): C, 51.48; H, 4.75; N, 30.02%.

Found: C, 51.53; H, 4.86; N, 29.84%.

#### 5-Amino-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile **14**

2-[(5-Amino-1,2-dimethyl-1*H*-imidazol-4-yl)-methylsulfanyl-methylene]malononitrile **13** (0.20 g, 0.86 mmol) was placed in a flask with MeOH (50 mL) and heated to 60 °C. NaOH (0.18 g) in H<sub>2</sub>O (2 mL) was added to the reaction mixture. The reaction was followed by TLC (EtOAc: MeOH 10:1) and after 20

min. showed one fluorescent spot (rf 0.67). The mixture was cooled to rt and the precipitate collected, recrystallised from DMF and identified as the product **14** (0.17 g, 86%); off-white crystals; mp 300 °C.

IR (KBr): 517, 639, 899, 1370, 1425, 1488, 1560, 1585, 1648, 2202, 2931, 3338, 3412 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 2.45 (s, 3H, C-CH<sub>3</sub>), 3.03 (s, 3H, S-CH<sub>3</sub>), 3.54 (s, 3H, N-CH<sub>3</sub>), 6.54 (br s, 2H, NH<sub>2</sub>).

<sup>13</sup>C NMR (d<sub>6</sub>-DMSO): δ = 14.38 (C-CH<sub>3</sub>), 16.74 (S-CH<sub>3</sub>), 28.64 (N-CH<sub>3</sub>), 83.63 (C6), 117.20 (CN), 126.01 (C1a), 144.52 (C3a), 149.82 (C2), 151.59 (C7), 157.94 (C5).

MS (EI/LR): *m/z* (%) = 233 (100) [M<sup>+</sup>], 232 (24), 218 (9), 206 (11), 200 (25), 188 (12), 187 (27), 186 (15), 145 (13), 123 (12), 117 (12), 109 (18), 105 (23), 104 (44), 95 (21), 91 (45), 82 (44), 77 (56), 69 (34), 67 (43).

Anal. Calcd for C<sub>10</sub>H<sub>11</sub>N<sub>5</sub>S (233.29): C, 51.48; H, 4.75; N, 30.02.

Found: C, 51.33; H, 4.67; N, 29.90.

#### ***N*-(6-Cyano-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-formimidic acid ethyl ester **15****

5-Amino-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile **14** (5.96 g, 25.5 mmol), triethyl orthoformate (500 mL) and *para*-toluenesulphonic acid monohydrate (0.81 g, 4.3 mmol) were placed in a flask fitted with a Claisen head and condenser. The mixture was heated to 150 °C (4 h). Activated carbon was then added and the hot mixture filtered. The precipitate, which appeared on cooling, was collected and washed with a little Et<sub>2</sub>O giving the product **15** (6.43 g, 87%); fine colourless crystals; mp 197-200 °C.

IR (KBr): 1196, 1226, 1559, 1580, 1627, 2214, 2935 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 1.36 (t, *J* = 7.0 Hz, 3H, CH<sub>3</sub>CH<sub>2</sub>), 2.56 (s, 3H, C-CH<sub>3</sub>), 3.11 (s, 3H, S-CH<sub>3</sub>), 3.69 (s, 3H, N-CH<sub>3</sub>), 4.37 (q, *J* = 7.0 Hz, 2H, CH<sub>3</sub>CH<sub>2</sub>), 8.56 (s, 1H, CH-OEt).

<sup>13</sup>C NMR (d<sub>6</sub>-DMSO): δ = 13.84 (C-CH<sub>3</sub>), 13.98 (CH<sub>3</sub>CH<sub>2</sub>), 16.28 (S-CH<sub>3</sub>), 28.35 (N-CH<sub>3</sub>), 63.34 (CH<sub>3</sub>CH<sub>2</sub>), 94.81 (C6), 115.78 (CN), 130.10 (C1a), 144.19 (C3a), 147.75 (C2), 153.98 (C7), 156.10 (EtOC=N), 160.45 (C5).

MS (EI): *m/z* (%) = 289 (21) [M<sup>+</sup>], 260 (100), 244 (46), 232 (15), 186 (12), 171 (10), 145 (12), 135 (12), 104 (19), 91 (15), 77 (13), 56 (57), 46 (12), 42 (18).

Anal. Calcd for C<sub>13</sub>H<sub>15</sub>N<sub>5</sub>OS (289.36): C, 53.92; H, 5.22; N, 24.29.

Found: C, 53.75; H, 5.00; N, 24.07.

#### **2,3-Dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta [*b*]naphthalen-8-ylamine **16****

*N*-(6-Cyano-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-formimidic acid ethyl ester **15** (3.03 g, 10.5 mmol) was added to EtOH (300 mL) saturated with ammonia. The mixture was stirred at rt (1 h) and then heated under reflux overnight. The mixture was cooled in a freezer and the precipitate collected and identified as the product **16** (2.31 g, 85%); fine colourless crystals; mp 252-255 °C. An analytical sample was recrystallised from *iso*-propanol.

IR (KBr): 1346, 1401, 1429, 1455, 1500, 1521, 1551, 1576, 1638, 2360, 2937, 3075, 3282, 3434 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 2.66 (s, 3H, C-CH<sub>3</sub>), 2.94 (s, 3H, S-CH<sub>3</sub>), 3.75 (s, 3H, N-CH<sub>3</sub>), 8.32 (br s, 2H, NH<sub>2</sub>), 8.40 (s, 1H, CH).

<sup>13</sup>C NMR (d<sub>6</sub>-DMSO): δ = 14.45 (C-CH<sub>3</sub>), 19.48 (S-CH<sub>3</sub>), 28.27 (N-CH<sub>3</sub>), 105.43 (C8a), 133.47 (C1a), 135.41 (C3a), 150.56 (C9), 155.78 (C2), 155.90 (C6), 157.88 (C4a), 163.70 (C8).

MS (EI): *m/z* (%) = 260 (88) [M<sup>+</sup>], 254 (13), 245 (21), 234 (12), 233 (53), 227 (75), 218 (16), 214 (22), 212 (44), 210 (68), 204 (71), 197 (100), 187 (85), 179 (59), 169 (62).

Anal. Calcd for C<sub>11</sub>H<sub>12</sub>N<sub>6</sub>S (260.32): C, 50.75; H, 4.65; N, 32.28.

Found: C, 50.60; H, 4.44; N, 32.28.

#### **2,3-Dimethyl-9-methylsulfanyl-3,7-dihydro-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-one **17****

2,3-Dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-ylamine **16** (1.00 g, 3.8 mmol) in 2M HCl (100 mL) was heated under reflux (2 h). The solution was cooled in an ice bath and basified with aqueous ammonia. The resulting precipitate was collected, washed with H<sub>2</sub>O, EtOH and finally Et<sub>2</sub>O giving the product **17** (0.74 g, 74%); colourless solid; mp >350 °C.

IR (KBr): 956, 1242, 1314, 1324, 1351, 1373, 1423, 1472, 1548, 1575, 1615, 1668, 2629, 2910, 3046 cm<sup>-1</sup>.

<sup>1</sup>H NMR (TFA): δ = 3.12 (s, 3H, C-CH<sub>3</sub>), 3.15 (s, 3H, S-CH<sub>3</sub>), 4.17 (s, 3H, N-CH<sub>3</sub>), 9.56 (s, 1H, CH).

<sup>13</sup>C NMR (TFA): δ = 14.74 (C-CH<sub>3</sub>), 20.18 (S-CH<sub>3</sub>), 33.08 (N-CH<sub>3</sub>), 126.42 (C8a), 149.03 (C1a), 151.31 (C3a), 154.42 (C9), 155.07 (C2), 161.66 (C6), 161.99 (C4a), 166.41 (C8).

MS (EI): *m/z* (%) = 261 (31) [M<sup>+</sup>], 228 (15), 187 (9), 105 (10), 91 (17), 77 (9), 56 (12), 44 (100).

Anal. Calcd for C<sub>11</sub>H<sub>11</sub>N<sub>5</sub>SO (261.30): C, 50.56; H, 4.24; N, 26.80.

Found: C, 50.54; H, 4.06; N, 26.65.

***N*-(6-Cyano-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-*N*'-propyl-formamidine **18****

*N*-(6-cyano-2,3-dimethyl-7-methylsulfanyl-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-formimidic acid ethyl ester **15** (0.50 g, 1.7 mmol) and *n*-propylamine (0.70 mL, 8.5 mmol) in EtOH (25 mL) were allowed to stand at rt (18 h). The solvent and excess amine were removed under reduced pressure. The solid residue was recrystallised (EtOAc and petroleum ether) and identified as the product **18** (0.31 g, 58%); off-white crystals; mp 147–149 °C.

IR (KBr): 938, 959, 1151, 1195, 1250, 1349, 1373, 1423, 1475, 1574, 1615, 2212, 2873, 2929, 2958, 3243 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 0.97 (t, *J* = 7.5 Hz, 3H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.64 (m, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.05 (s, 3H, C-CH<sub>3</sub>), 3.34 (s, 3H, S-CH<sub>3</sub>), 3.38 (q, *J* = 6.5 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.62 (s, 3H, N-CH<sub>3</sub>), 8.09 (d, *J* = 4.5 Hz, 1H, CH), 8.52 (d, *J* = 4.5 Hz, 1H, NH).

<sup>13</sup>C NMR (d<sub>6</sub>-DMSO): δ = 11.44 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 13.89 (C-CH<sub>3</sub>), 16.17 (S-CH<sub>3</sub>), 21.49 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 28.07 (N-CH<sub>3</sub>), 42.16 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 94.16 (C6), 116.89 (CN), 128.27 (C1a), 143.56 (C3a), 148.16 (C2), 152.30 (C7), 153.21 (N=C-N), 160.11 (C5).

MS (EI): *m/z* (%) = 302 (26) [M<sup>+</sup>], 287 (10), 269 (12), 244 (9), 200 (13), 187 (22), 56 (14).

Anal. Calcd for C<sub>14</sub>H<sub>18</sub>N<sub>6</sub>S (302.4): C, 55.61; H, 6.00; N, 27.79.

Found: C, 55.64; H, 5.79; N, 27.61.

***N*-Acetyl-*N*-(2,3-dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-acetamide **20****

To a suspension of 2,3-dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-ylamine **16** (2.00 g, 7.7 mmol) in pyridine (27 mL) was added Ac<sub>2</sub>O (20 mL). The mixture was heated under reflux (2 h) and then poured onto ice water (50 mL). The product was extracted into CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL), dried (MgSO<sub>4</sub>) and the solvent reduced by half (~20 mL). Et<sub>2</sub>O was added and the solution left to cool overnight. The precipitate was collected, dried under high vacuum at 100 °C and identified as the product **20** (2.01 g, 76% yield); fine yellow crystals; mp 178–183 °C.

IR (KBr): 1163, 1219, 1296, 1353, 1404, 1479, 1539, 1574, 1608, 1731, 2341, 2359, 2930, 3007 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.30 (s, 6H, NC(O)CH<sub>3</sub>), 2.66 (s, 3H, C-CH<sub>3</sub>), 3.17 (s, 3H, S-CH<sub>3</sub>), 3.86 (s, 3H, N-CH<sub>3</sub>), 9.29 (s, 1H, CH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.01 (C-CH<sub>3</sub>), 20.11 (S-CH<sub>3</sub>), 27.10 (NC(O)CH<sub>3</sub>), 28.93 (N-CH<sub>3</sub>), 115.15

(C8a), 136.06 (C1a), 138.28 (C3a), 152.94 (C9), 155.70 (C2), 157.79 (C6), 157.85 (C4a), 160.60 (C8), 171.67 (NC(O)CH<sub>3</sub>).

MS (EI): *m/z* (%) = 344 (3) [M<sup>+</sup>], 301 (3), 269 (12), 255 (19), 245 (12), 227 (3), 171 (6), 135 (2), 94 (6), 82 (3), 56 (12), 43 (100).

Anal. Calcd for C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub>S (344.39): C, 52.31; H, 4.68; N, 24.40.

Found: C, 52.43; H, 4.36; N, 24.19.

**(2,3-Dimethyl-9-methanesulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid tert-butyl ester **21****

2,3-Dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-ylamine **16** (1.00 g, 3.8 mmol) was suspended in dry 1,4-dioxane (100 mL) and heated to 120 °C. When all the starting material had dissolved, di-*tert*-butyl dicarbonate (4.19 g, 19.2 mmol) was added and the solution stirred (5 h) after which TLC (MeOH) showed that all starting material had reacted. The solvent was removed by evaporation and the resulting solid treated with Et<sub>2</sub>O (50 mL). The solid was then collected, washed with further Et<sub>2</sub>O (2 x 25 mL) and identified as the product **21** (1.15 g, 83% yield); yellow solid; mp 167 °C (decomp.).

IR (KBr): 1060, 1152, 1248, 1305, 1353, 1372, 1426, 1505, 1580, 1697, 1758, 2923, 2976, 3422 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.61 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.77 (s, 3H, C-CH<sub>3</sub>), 2.87 (s, 3H, S-CH<sub>3</sub>), 3.91 (s, 3H, N-CH<sub>3</sub>), 9.10 (s, 1H, CH), 11.49 (br s, 1H, NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.08 (C-CH<sub>3</sub>), 20.74 (S-CH<sub>3</sub>), 28.25 (O-(CH<sub>3</sub>)<sub>3</sub>), 28.97 (N-CH<sub>3</sub>), 82.21 ((Me)<sub>3</sub>-C-O), 108.08 (C8a), 131.27 (C1a), 138.25 (C3a), 149.79 (C9), 151.74 (HN-COO), 156.09 (C2), 156.46 (C6), 158.64 (C4a), 159.72 (C8).

Anal. Calcd for C<sub>16</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (360.44): C, 53.32; H, 5.59; N, 23.32.

Found: C, 53.03; H, 5.43; N, 23.57.

***N*-Acetyl-*N*-(9-methanesulfinyl-2,3-dimethyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-acetamide **22****

*N*-Acetyl-*N*-(2,3-dimethyl-9-methylsulfanyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-acetamide **20** (194 mg, 0.56 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and cooled to 0 °C. 3-Chloroperoxybenzoic acid (50–55%)(194 mg, 0.56 mmol) was added and the mixture stirred (1.5 h). The organic layer was then washed with sat. aq NaHCO<sub>3</sub> (2 x 20 mL) and H<sub>2</sub>O (2 x 20 mL). The organic layer was then dried (MgSO<sub>4</sub>) and the solvent removed under reduced pressure. The crude material was dissolved in EtOAc and the solvent reduced until crystallisation began. After cooling, the solid was collected

and identified as the product **22** (22 mg, 11% yield); yellow crystals; mp 191–192 °C.

IR (KBr): 568, 599, 640, 685, 926, 867, 1006, 1040, 1067, 1157, 1230, 1301, 1369, 1423, 1475, 1514, 1577, 1616, 1698, 1720, 2922, 3006 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.12 (s, 3H, CO-CH<sub>3</sub>), 2.65 s, (3H, CO-CH<sub>3</sub>), 2.88 (s, 3H, C-CH<sub>3</sub>), 3.45 (s, 3H, SO-CH<sub>3</sub>), 4.01 (s, 3H, N-CH<sub>3</sub>), 9.46 (s, 1H, CH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.97 (C-CH<sub>3</sub>), 26.76 (NC(O)CH<sub>3</sub>), 28.15 (NC(O)CH<sub>3</sub>), 29.69 (N-CH<sub>3</sub>), 40.86 (SO-CH<sub>3</sub>), 113.77 (C8a), 136.33 (C3a), 138.37 (C1a), 156.00 (C9), 156.36 (C2), 156.82 (C6), 160.42 (C4a), 164.18 (C8), 170.72 (NC(O)CH<sub>3</sub>), 174.51 (NC(O)CH<sub>3</sub>).

MS (EI): *m/z* (%) = 361 (3) [M+H<sup>+</sup>], 345 (9), 303 (6), 277 (4), 255 (85), 246 (6), 200 (6), 120 (26), 119 (54), 111 (8), 97 (12), 77 (100).

Anal. Calcd for C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>O<sub>3</sub>S (360.39): C, 49.99; H, 4.47; N, 23.32.

Found: C, 49.73; H, 4.52; N, 23.06.

**(9-Methanesulfinyl-2,3-dimethyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **23****

Using the procedure described for compound **22**, compound **23** was obtained from (2,3-dimethyl-9-methanesulfanyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **21** (1.00 g, 2.8 mmol); yield: 0.66 g, 63%; pale yellow, crystalline solid; mp 172 °C (decomp.).

IR (KBr): 749, 812, 839, 879, 927, 958, 1022, 1074, 1146, 1225, 1252, 1307, 1373, 1429, 1493, 1527, 1588, 1752, 2728, 2927, 2978, 3494 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.59 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.79 (s, 3H, C-CH<sub>3</sub>), 3.12 (s, 3H, SO-CH<sub>3</sub>), 3.95 (s, 3H, N-CH<sub>3</sub>), 9.22 (s, 1H, CH), 12.28 (br s, 1H, NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.56 (C-CH<sub>3</sub>), 28.66 (O-C(CH<sub>3</sub>)<sub>3</sub>), 29.57 (N-CH<sub>3</sub>), 39.84 (SO-CH<sub>3</sub>), 82.18 ((Me)<sub>3</sub>-C-O), 107.99 (C8a), 134.44 (C3a), 136.30 (C1a), 151.54 (C2), 153.33 (HN-COO), 157.30 (C9), 158.27 (C6), 158.81 (C4a), 162.37 (C8).

***N*-Acetyl-*N*-(9-methanesulfonyl-2,3-dimethyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-acetamide **24****

*N*-Acetyl-*N*-(2,3-dimethyl-9-methylsulfanyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-acetamide **20** (2.00 g, 5.8 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and cooled to 0 °C. 3-Chloroperoxybenzoic acid (50–55%) (4.00 g, 11.6 mmol) was added and the mixture stirred (4 h). The organic layer was diluted with a further portion of CH<sub>2</sub>Cl<sub>2</sub> (50 mL), washed with H<sub>2</sub>O (2 x 100 mL) and dried (MgSO<sub>4</sub>). After the solvent had been removed

under reduced pressure, the crude solid was recrystallised from EtOAc and identified as the product **24** (1.51 g, 67%); orange crystals; mp 185–186 °C.

IR (KBr): 537, 579, 640, 755, 933, 1009, 1038, 1122, 1152, 1211, 1236, 1259, 1310, 1353, 1366, 1404, 1426, 1485, 1517, 1561, 1577, 1623, 1706, 1733, 2924, 3016 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.48 (s, 6H, CO-CH<sub>3</sub>), 2.81 (s, 3H, C-CH<sub>3</sub>), 3.83 (s, 3H, SO<sub>2</sub>-CH<sub>3</sub>), 3.98 (s, 3H, N-CH<sub>3</sub>), 9.42 (s, 1H, CH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.44 (C-CH<sub>3</sub>), 27.89 (C(O)CH<sub>3</sub>), 29.36 (N-CH<sub>3</sub>), 48.90 (S-CH<sub>3</sub>), 112.17 (C8a), 132.79 (C3a), 132.83 (C1a), 143.21 (C2), 155.55 (C9), 155.86 (C6), 160.25 (C4a), 163.78 (C8), 173.18 (C(O)CH<sub>3</sub>).

MS (EI): *m/z* (%) = 377 (2%) [M+H<sup>+</sup>], 299 (4), 255 (35), 215 (4), 200 (7), 177 (4), 163 (4), 140 (4), 119 (9), 111 (18), 97 (24), 77 (100), 60 (12).

Anal. Calcd for C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>O<sub>4</sub>S (376.39): C, 49.87; H, 4.28; N, 22.33.

Found: C, 47.69; H, 4.05; N, 22.11.

**(9-Methanesulfonyl-2,3-dimethyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)carbamic acid *tert*-butyl ester **25****

Using the procedure described for compound **24**, compound **25** was obtained from (2,3-dimethyl-9-methanesulfanyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **21** (2.00 g, 5.5 mmol); yield: 1.42 g, 65%; dark gold, crystalline solid; mp 100 °C (decomp.).

IR (KBr): 774, 840, 1145, 1218, 1245, 1297, 1353, 1375, 1414, 1509, 1578, 1752, 2925, 2976, 3422 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.59 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 2.79 (s, 3H, C-CH<sub>3</sub>), 3.92 (s, 3H, SO<sub>2</sub>-CH<sub>3</sub>), 3.95 (s, 3H, N-CH<sub>3</sub>), 9.16 (s, 1H, CH), 10.03 (br s, 1H, NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.69 (C-CH<sub>3</sub>), 28.53 (O-C(CH<sub>3</sub>)<sub>3</sub>), 29.56 (N-CH<sub>3</sub>), 48.26(SO<sub>2</sub>-CH<sub>3</sub>), 82.44 ((Me)<sub>3</sub>-C-O), 104.32 (C8a), 132.17 (C3a), 133.95 (C1a), 150.91 (HN-COO), 154.93 (C2), 155.97 (C9), 156.83 (C6), 157.16 (C4a), 163.16 (C8).

**(9-Ethoxy-2,3-dimethyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **26****

(9-Methanesulfonyl-2,3-dimethyl-3H-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **25** (0.50 g, 1.3 mmol) was dissolved in EtOH (50 mL) with stirring. Sodium metal (0.10 g, 2.5 mmol) was then added and the mixture stirred for 30 min. at which point TLC (EtOAc: MeOH 5:1) showed the disappearance of the starting material and a new slower running spot (rf: 0.38). The EtOH was removed under reduced pressure and the residue redissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The organic layer was

then washed with H<sub>2</sub>O (2 x 50 mL), dried (MgSO<sub>4</sub>) and the solvent removed. The solid product was then purified by column chromatography (3:1 EtOAc:MeOH) and the relevant fractions combined to give compound **26** (0.11 g, 24%); colourless solid; mp: 204 °C (decomp.).

IR (KBr): 815, 949, 1016, 1060, 1109, 1143, 1241, 1356, 1369, 1380, 1466, 1507, 1555, 1597, 1624, 1663, 1751, 2973, 3342 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.58 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 1.67 (t, *J* = 7.0 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>), 2.65 (s, 3H, C-CH<sub>3</sub>), 3.86 (s, 3H, N-CH<sub>3</sub>), 5.34 (q, *J* = 7.0 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 9.01 (s, 1H, CH), 10.40 (br s, 1H, NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 15.02 (O-CH<sub>2</sub>CH<sub>3</sub>), 15.75 (C-CH<sub>3</sub>), 28.54 (O-C(CH<sub>3</sub>)<sub>3</sub>), 29.26 (N-CH<sub>3</sub>), 72.23 (O-CH<sub>2</sub>CH<sub>3</sub>), 82.10 ((CH<sub>3</sub>)<sub>3</sub>-C-O), 100.20 (C8a), 122.51 (C1a), 149.85 (C3a), 152.39 (HN-COO), 155.45 (C2), 155.63 (C6), 157.21 (C4a), 157.42 (C8), 158.92 (C9).

MS (EI): *m/z* (%) = 359 (14) [M+H<sup>+</sup>], 259 (100), 244 (24), 222 (67), 204 (24), 192 (22), 176 (22), 150 (30), 148 (42), 135 (53), 122 (71), 100 (64), 98 (76), 84 (76), 72 (86).

HRMS(ES): *m/z* calcd for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub> [M+H<sup>+</sup>]: 359.1826; found: 359.1825.

### (2,3-Dimethyl-9-propylamino-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl) carbamic acid *tert*-butyl ester **27**

(9-Methanesulfonyl-2,3-dimethyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **25** (0.86 g, 2.2 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (75 mL). To this solution was added *n*-propylamine (0.18 mL, 2.2 mmol) and stirring was maintained at rt (2 h). The solvent was removed under reduced pressure and the resulting solid dried under high vacuum at 70 °C (12 h) to give the product **20** (0.80 g, 98%); dark yellow solid; mp 218 °C (decomp.).

IR (KBr): 1003, 1071, 1114, 1157, 1218, 1253, 1384, 1439, 1528, 1586, 1652, 1700, 2862, 2965, 3408 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.15 (t, *J* = 7.0 Hz, 3H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.53 (s, C(CH<sub>3</sub>)<sub>3</sub>), 1.77 (m, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.55 (s, 3H, C-CH<sub>3</sub>), 3.74 (s, 3H, N-CH<sub>3</sub>), 4.18 (q, *J* = 6.0 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 8.05 (s, 1H, CH), 11.63 (t, *J* = 6.0 Hz, 1H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 13.60 (br s, 1H, Boc-NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 11.82 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 14.7 (C-CH<sub>3</sub>), 23.49 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 28.57 (O-C(CH<sub>3</sub>)<sub>3</sub>), 29.00 (N-CH<sub>3</sub>), 47.57 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 80.24 ((CH<sub>3</sub>)<sub>3</sub>-C-O), 98.04 (C8a), 120.13 (C1a), 142.97 (C3a), 148.94 (C2), 149.19 (C9), 151.78 (C4a), 156.50 (C6), 160.73 (HNCOO), 163.65 (C8).

### (9-Butylamino-2,3-dimethyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)- carbamic acid *tert*-butyl ester **28**

Using the procedure described for compound **27**, compound **28** was obtained from (9-methanesulfonyl-2,3-dimethyl-3*H*-1,3,4,5,7-pentaaza-cyclopenta[*b*]naphthalen-8-yl)-carbamic acid *tert*-butyl ester **25** (1.00 g, 2.6 mmol); yield: 0.91 g 93%; dark orange solid; mp 220 °C (decomp.).

IR (KBr): 1041, 1157, 1264, 1367, 1585, 1700, 1718, 1621, 1646, 2867, 2924, 2964, 3439 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.99 (t, *J* = 7.0 Hz, 3H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.52 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 1.62-1.76 (m, 4H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> and NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.54 (s, 3H, C-CH<sub>3</sub>), 3.72 (s, 3H, N-CH<sub>3</sub>), 4.21 (q, *J* = 6.0 Hz, 2H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 8.04 (s, 1H, CH), 11.58 (br s, 1H, NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 13.62 (br s, 1H, Boc-NH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 14.40 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 14.68 (C-CH<sub>3</sub>), 20.29 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 28.60 (O-C(CH<sub>3</sub>)<sub>3</sub>), 29.00 (N-CH<sub>3</sub>), 32.28 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 45.54 (NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 80.22 ((CH<sub>3</sub>)<sub>3</sub>-C-O), 98.02 (C8a), 120.13 (C1a), 143.00 (C3a), 148.91 (C2), 149.20 (C9), 151.77 (C4a), 156.50 (C6), 160.74 (HNCOO), 163.68 (C8).

### 5-Amino-4-(1-methylsulfonyl-2,2-dicyanovinyl)-1-(2'-deoxy-3',5'-di-*O*-*p*-toluoyl-β-D-ribofuranosyl) imidazole **30**

1-(2'-Deoxy-3',5'-di-*O*-*p*-toluoyl-β-D-erythro-pentofuranosyl)-5-nitroimidazole **29**<sup>99</sup> (3.00 g, 6.4 mmol), and 5% Pd/C catalyst (3.00 g) were placed in dry THF (120 mL) and the mixture was hydrogenated at rt and atmospheric pressure, with vigorous stirring (2 h). The solution was filtered through dry celite, under argon, into a flask containing 2-(bis-methylsulfonyl-methylene)-malononitrile **9** (5.50 g, 32.3 mmol). The celite was washed with a further portion of THF (120 mL). The reaction was stirred at 50 °C, under argon, overnight giving a dark brown solution. The mixture was evaporated to dryness and the residue treated with liquid nitrogen-chilled EtOAc (200 mL). The solution was then filtered to give the crude product which was purified by column chromatography eluting with CH<sub>2</sub>Cl<sub>2</sub>, to remove excess starting material, and then with 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>. The relevant fractions were combined and evaporated to dryness to give the amine **30** (0.53 g, 15%) brown crystalline solid; mp 98-100 °C.

IR (KBr): 752, 1102, 1178, 1209, 1270, 1311, 1377, 1449, 1486, 1508, 1544, 1578, 1611, 1720, 2209, 2923, 3035, 3329 cm<sup>-1</sup>.

<sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ = 2.30 (s, 3H, S-CH<sub>3</sub>), 2.39 (s, 3H, Ar-CH<sub>3</sub>), 2.41 (s, 3H, Ar-CH<sub>3</sub>), 2.70 (m, 1H, 2φ-CH), 2.88 (m, 1H, 2φ-CH), 4.54 (m, 3H, 5φ-CH<sub>2</sub> and 4φ-CH), 5.63 (d, *J* = 4.0 Hz, 1H, 3φ-CH), 6.19 (m, 1H, 1φ-CH), 7.18 (br s, 2H, NH<sub>2</sub>), 7.34 (d, *J* = 8.0 Hz, 2 x 2H, Ar-*H*), 7.38 (d, *J* = 8.0 Hz, 2H, 2 x Ar-*H*), 7.79 (s, 1H, imidazole(2)-*H*), 7.88 (d, *J* = 8.0 Hz, 2H, 2 x Ar-*H*), 7.97 (d, *J* = 8.0 Hz, 2H, 2 x Ar-*H*).

$^{13}\text{C}$  NMR ( $d_6$ -DMSO):  $\delta$  = 17.61 (S-CH<sub>3</sub>), 21.09 (2 x Ar-CH<sub>3</sub>), 36.08 (C2 $\phi$ ), 64.02 (C5 $\phi$ ), 64.40 (C3'), 74.80 (C(CN)<sub>2</sub>), 81.59 (C1 $\phi$ ), 82.73 (C4 $\phi$ ), 114.16 (C4-imidazole), 126.41 (2 x CN), 129.22 (2 x ArC), 129.30 (4 x ArC), 129.45 (4 x ArC), 132.29 (C2-imidazole), 143.82 (C-CH<sub>3</sub>), 144.04 (C-CH<sub>3</sub>), 145.42 (C5-imidazole), 165.08 (C=O), 165.38 (C=O), 167.13 (C=C(CN)<sub>2</sub>).

MS (EI):  $m/z$  (%) = 558 (5) [M+H<sup>+</sup>], 234 (52), 219 (10), 179 (13), 154 (43), 153 (15), 119 (27), 115 (58), 98 (100), 81 (85).

Anal. Calcd. for C<sub>29</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub>S (557.62): C, 62.47; H, 4.88; N, 12.56.

Found: C, 62.30; H, 4.65, N, 12.26.

### Acknowledgment

We thank the EPSRC for a studentship (to JAC) and the EPSRC National Mass Spectrometry Service for mass spectra.

### References

- (1) Leonard, N. J.; Sprecker, M. A.; Morrice, A. G. *J. Am. Chem. Soc.*, **1976**, *98*, 3987.
- (2) Scopes, D. I.; Barrio, J. R.; Leonard, N. J. *Science*, **1977**, *195*, 296.
- (3) Leonard, N. J.; Keyser, G. E. *Proc. Nat. Acad. Sci. USA*, **1979**, *76*, 4262.
- (4) Leonard, N. J. *Acc. Chem. Res.*, **1982**, *15*, 128.
- (5) Lessor, R. A.; Gibson, K. J.; Leonard, N. J. *Biochemistry*, **1984**, *23*, 3868.
- (6) Seley, K. L.; Januszczuk, P.; Hagos, A.; Zhang, L.; Dransfield, D. T. *J. Med. Chem.*, **2000**, *43*, 4877.
- (7) Minakawa, N.; Kojima, N.; Hikishama, S.; Sasaki, T.; Kiyosue, A.; Atsumi, N.; Ueno, Y.; Matsuda, A. *J. Am. Chem. Soc.*, **2003**, *125*, 9970.
- (8) Liu, H.; Gao, J.; Maynard, L.; Saito, Y. D.; Kool, E. T. *J. Am. Chem. Soc.*, **2004**, *126*, 1102.
- (9) Krueger, A. T.; Lu, H.; Lee, A. H. F.; Kool, E. T. *Acc. Chem. Res.*, **2007**, *40*, 141.
- (10) Humphries, M. J.; Ramsden, C. A. *Synthesis*, **1999**, 985.
- (11) Clayton, R.; Davis, M. L.; Fraser, W.; Li, W.; Ramsden, C. A. *Synlett*, **2002**, 1483.
- (12) Davis, M. L.; Fraser, W.; Ramsden, C. A. *manuscript in preparation*.
- (13) Al-Shaar, A. H. M.; Gilmour, D. W.; Lythgoe, D. J.; McClenaghan, I.; Ramsden, C. A. *J. Chem. Soc. Perkin Trans. I*, **1992**, 2779.
- (14) Al-Shaar, A. H. M.; Chambers, R. K.; Gilmour, D. W.; Lythgoe, D. J.; McClenaghan, I.; Ramsden, C. A. *J. Chem. Soc. Perkin Trans. I*, **1992**, 2789.
- (15) Lythgoe, D. J.; Ramsden, C. A. *Adv. Heterocycl. Chem.*, **1994**, *61*, 1.
- (16) Mashraqui, S. H.; Hariharasubrahmanian, H. *J. Chem. Res.*, **1999**, *8*, 492.
- (17) Dewar, M. J. S.; Zuebisch, E. G.; Healy, E. F.; Stewart, J. J. P. *J. Am. Chem. Soc.*, **1985**, *107*, 3902.
- (18) Finnerty, J.; Mitschke, U.; Wentrup, C. *J. Org. Chem.*, **2002**, *67*, 1084.

Please place the graphical abstract and short title of the article here. The short title will be used as a running header.

**Manuscript submission checklist**

ÉStatement of significance of work.

ÉFull mailing address, telephone and fax numbers, and email address of the corresponding author.

ÉPaper save as a PDF file.

ÉOriginal Word file.

ÉOriginal graphic files.

ÉGraphical abstract.